High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
The right dose of daunorubicin (DNR) for the treatment of newly diagnosed acute myeloid leukemia (AML) is uncertain. Previous trials have shown conflicting results concerning the efficacy of high or low doses of daunorubicin to induction chemotherapy for newly diagnosed AML. A systematic review and...
Saved in:
Main Authors: | Qiang Gong, Lixin Zhou, Shuangnian Xu, Xi Li, Yunding Zou, Jieping Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0125612 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High-dose versus Standard-dose Daunorubicin in Induction Chemotherapy for Acute Myeloid Leukemia: A Meta-Analysis
by: Bibi Kulsoom, et al.
Published: (2025-06-01) -
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment
by: Oudai Alkabbani, et al.
Published: (2025-07-01) -
Tasigna advantage in treatment of newly diagnosed chronic myeloid leukemia: results of «Novartis research»
by: article Editorial
Published: (2022-11-01) -
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia
by: Tracy Murphy, et al.
Published: (2025-07-01) -
Association of Pretreatment Serum Indirect Bilirubin Levels With Prognostic and Therapeutic Value in Patients With Newly Diagnosed Acute Myeloid Leukemia
by: Chunfang Kong, et al.
Published: (2025-02-01)